Fluoroazomycin arabinoside F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Fluoroazomycin arabinoside F-18
Accession Number
DB15134
Type
Small Molecule
Groups
Investigational
Description

Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).

Structure
Thumb
Synonyms
  • 18F-FAZA
Categories
UNII
UG7I3Y42PV
CAS number
864084-85-5
Weight
Average: 246.185
Monoisotopic: 246.062983101
Chemical Formula
C8H10FN3O5
InChI Key
LPZSRGRDVVGMMX-FJBGPTLJSA-N
InChI
InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1/i9-1
IUPAC Name
(2S,3S,4S,5S)-2-[(¹⁸F)fluoromethyl]-5-(2-nitro-1H-imidazol-1-yl)oxolane-3,4-diol
SMILES
O[C@H]1[C@H](O)[C@H](O[C@@H]1C[18F])N1C=CN=C1[N+]([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
2104828

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Enrolling by InvitationDiagnosticNon-Rhabdo. Soft Tissue Sarcoma / Rhabdomyosarcomas1
1, 2TerminatedDiagnosticNeuroendocrine Tumours / Renal Cell Adenocarcinoma1
2TerminatedDiagnosticNeoplasms, Breast1
Not AvailableRecruitingDiagnosticSarcomas1
Not AvailableRecruitingTreatmentPancreatic Ductal Adenocarcinoma1
Not AvailableWithdrawnDiagnosticAdenocarcinoma of the Pancreas / Advanced Disease / Metastatic Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.0 mg/mLALOGPS
logP-0.45ALOGPS
logP-0.19ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-0.016ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.65 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.71 m3·mol-1ChemAxon
Polarizability20.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:52 / Updated on November 02, 2019 03:30